In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks to ...

However, the drugmaker's prospects look so strong that not only should it soon join the $1 trillion club, but it could even ...

Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

Sima Sistani, CEO of WeightWatchers, announced her departure from the weight-loss company, which has struggled to adapt in ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...